Corrigendum to “Surface plasmon resonance and circular dichroism characterization of cucurbitacins binding to serum albumins for early pharmacokinetic profiling” [J. Pharm. Biomed. Anal. 122 (2016) 166–172]

Fabini, Edoardo; Fiori, Giovana Maria Lanchoti; Tedesco, Daniele; Lopes, Norberto Peporine; Bertucci, Carlo

doi:10.1016/j.jpba.2016.03.054

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An advantage of SPR technology is its ability to accurately quantify the molecular interaction rate, binding level, and kinetic constants. [ 52 ] We evaluated the binding kinetics of the recombinant pUC19 and pCDH PCR amplicons to their corresponding dRNPs using real‐time SPR monitoring with dRNP‐functionalized chips. In both the ‐0.3k and ‐0.8k groups, the mutagenesis of ‐Mut3 resulted in the fastest association rate, presenting the highest affinitive property ( Figure A,B).…”

Section: Resultsmentioning

confidence: 99%

A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

et al. 2022

View full text Add to dashboard Cite

The clustered regularly interspaced short palindromic repeats (CRISPR) molecular system has emerged as a promising technology for the detection of nucleic acids. Herein, the development of a surface plasmon resonance (SPR) sensor that is functionalized with a layer of locally grown graphdiyne film, achieving excellent sensing performance when coupled with catalytically deactivated CRISPR‐associated protein 9 (dCas9), is reported. dCas9 protein is immobilized on the sensor surface and complexed with a specific single‐guide RNA, enabling the amplification‐free detection of target sequences within genomic DNA. The sensor, termed CRISPR‐SPR‐Chip, is used to successfully analyze recombinant plasmids with only three‐base mutations with a limit of detection as low as 1.3 fM. Real‐time monitoring CRISPR‐SPR‐Chip is used to analyze clinical samples of patients with Duchenne muscular dystrophy with two exon deletions, which are detected without any pre‐amplification step, yielding significantly positive results within 5 min. The ability of this novel CRISPR‐empowered SPR (CRISPR‐eSPR) sensing platform to rapidly, precisely, sensitively, and specifically detect a target gene sequence provides a new on‐chip optic approach for clinical gene analysis.

show abstract

Section: Resultsmentioning

confidence: 99%

A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

et al. 2022

View full text Add to dashboard Cite

show abstract

Novel Multifunctional Meta‐Surface Plasmon Resonance Chip Microplate for High‐Throughput Molecular Screening

Chen,

Zhang,

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

The utilization of surface plasmon resonance (SPR) sensors for real‐time label‐free molecular interaction analysis is already being employed in the fields of in vitro diagnostics and biomedicine. However, the widespread application of SPR technology is hindered by its limited detection throughput and high cost. To address this issue, our study introduces a novel multifunctional MetaSPR high‐throughput microplate biosensor featuring 3D nanocup microarrays, aiming to achieve high‐throughput screening at a reduced cost and with enhanced speed. Different types of MetaSPR sensors and analytical detection methods have been developed for accurate subtype identification, epitope binding, affinity determination, antibody collocation, and other applications that have greatly promoted the screening and analysis of early antibody drugs. The MetaSPR platform combined with nano‐enhanced particles amplified the detection signal and improved the detection sensitivity, making it more convenient, sensitive, and efficient than traditional ELISA. Our findings demonstrated that the MetaSPR biosensor is a new practical technology detection platform that can improve the efficiency of biomolecular interaction studies with unlimited potential for new drug development.This article is protected by copyright. All rights reserved

show abstract

Free Electron Density Gradients Enhanced Biosensor for Ultrasensitive and Accurate Affinity Assessment of the Immunotherapy Drugs

Chen,

Fan,

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Accurate affinity assessments play an important role in drug discovery, screening, and efficacy evaluation. Label‐free affinity biosensors are recognized as a dependable and standard technology for addressing this challenge. This study constructs a free electron density gradient‐enhanced meta‐surface plasmon resonance (FED‐MSPR) biosensor through a finite‐difference time‐domain simulation model, the biosensor demonstrates superior detection performance in accurately determining affinity and kinetic rate constants. By controlling the dielectric properties of the metal on the surface of the nanocup arrays, the plasmon resonance effects are easily tuned without changing the nanostructure design. Compared with the single‐layer gold chip, the triple‐layer FED‐MSPR chip demonstrated a four‐fold improvement in resolution at the optimal resonance peak. Additionally, the sensitivity and figure of merit (FOM) of the multi‐layer chip increased by 3.5 and 7.99 times, respectively. Following modification with high‐ and low‐staggered carboxylation, the noise‐signal ratio and baseline stability of the real‐time kinetic curves based on these chips are significantly enhanced. The developed carboxylation FED‐MSPR platform is successfully used to perform affinity assays for Adalimumab and TNF‐α protein, resulting in favorable dynamic curves. These findings validate the proposed FED‐MSPR biosensor platform as cost‐effective, rapid, sensitive, and label‐free, facilitating real‐time quality control in drug development.

show abstract

Corrigendum to “Surface plasmon resonance and circular dichroism characterization of cucurbitacins binding to serum albumins for early pharmacokinetic profiling” [J. Pharm. Biomed. Anal. 122 (2016) 166–172]

Cited by 3 publications

References 0 publications

A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

Novel Multifunctional Meta‐Surface Plasmon Resonance Chip Microplate for High‐Throughput Molecular Screening

Free Electron Density Gradients Enhanced Biosensor for Ultrasensitive and Accurate Affinity Assessment of the Immunotherapy Drugs

Contact Info

Product

Resources

About